Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The history of protein phosphorylation (1)
- The history of protein phosphorylation (2)
- The history of protein phosphorylation (3)
- The history of protein phosphorylation (4)
- The history of protein phosphorylation (5)
- The history of protein phosphorylation (6)
- The history of protein phosphorylation (7)
- The history of protein phosphorylation (8)
- The history of protein phosphorylation (9)
- Stone age bioinformatics!
- Eukaryotic kinases have related catalytic domains
- PKA catalytic subunit bound to PKI and ATP
- A thousand and one protein kinases
- How many tyrosine kinases are there? (1)
- How many tyrosine kinases are there? (2)
- The history of tyrosine phosphorylation
- Reactions by kinases and phosphatases
- Unactivated insulin receptor TK catalytic domain
- Tyrosine phosphorylation and human disease (1)
- Tyrosine phosphorylation and human disease (2)
- How many protein kinases are there?
- Evolutionary kinomics: protein kinase families
- How many human PK and phosphatases? (1)
- How many human PK and phosphatases? (2)
- The human kinome (1)
- The human kinome (2)
- Human tyrosine kinases
- What is tyrosine phosphorylation used for?
- Nonreceptor tyrosine kinases
- Receptor tyrosine kinases (1)
- TM signaling by tyrosine phosphorylation
- RTK dimerization and catalytic activation
- FGF receptor dimer with bound FGF and heparin
- Mechanisms of RTK dimerization and activation
- Structural transition from IRK-0P to IRK-3P
- Receptor tyrosine kinase classes
- PDGF RTK activation and signaling
- Modular interac. domains in signal transduction
- RTK signaling through SH2 and PTB domains
- RTK signaling via the Grb2 SH2/SH3 adaptor
- Paradigms for signal pathway activation by RTK (1)
- Paradigms for signal pathway activation by RTK (2)
- Paradigms for signal pathway activation by RTK (3)
- Targets for receptor tyrosine kinases
- PDGF RTK activation and signaling
- PDGF receptor tyrosine kinase signaling
- Receptor Tyrosine Kinases (2)
- Insulin receptor tyrosine kinase signaling (1)
- Insulin receptor tyrosine kinase signaling (2)
- Insulin RTK signaling pathways
- Insulin/IGF1-IRS-PI3 kinase-mTOR signaling
- Tumor suppressors in PI3K/Akt/mTOR pathway
- TSC1 or TSC2-null MEFs show reduced IRS1
- mTOR dependent negative feedback loop
- Expression of Rheb decreases IRS levels
- Inhibitory effects of Rheb reversed by mTOR
- Inhibitory effects of Rheb reversed by S6K1
- Negative feedback loop reduces insulin signaling
- Multiple serine kinases act on IRS1 (1)
- Multiple serine kinases act on IRS1 (2)
- Model for Rheb/mTOR/S6K negative feedback
- Receptor Tyrosine Kinases (3)
- Eph family receptor tyrosine kinases (1)
- Eph family receptor tyrosine kinases (2)
- Ephs and ephrins mediate bidirectional signaling
- Repellant and attractant guidance cues
- coexpression of EphA and ephrin-A proteins
- Exogenous proteins trigger opposing responses
- Ephrin-A does not reduce EphA receptor activation
- Discrete EphA and ephrin-A localiza. in motor axon
- Differential membrane localization of EphA, ephrinA
- Domain-swapping chimeras
- Targeting ephrin-A to EphA membrane domains (1)
- Targeting ephrin-A to EphA membrane domains (2)
- Targeting EphA to ephrin-A membrane domains
- Compartmentalization insulates receptor diversity
- Protein kinases are implicated in diverse diseases
- Human cancer genes
- Cancer and the kinome
- Protein kinases/phosphatases and cancer (1)
- Protein kinases/phosphatases and cancer (2)
- The long road to the GLEEVEC cancer drug
- Acknowledgments
Topics Covered
- History of protein phosphorylation
- Protein kinase bioinformatics
- History of tyrosine phosphorylation and functions of tyrosine kinases
- Genomic catalogues of protein kinases (kinomes)
- The human kinome
- The evolution of kinomes
- The human tyrosine kinase subfamily
- Receptor and nonreceptor tyrosine kinases
- Activation of receptor tyrosine kinases by ligand-induced dimerization
- Signal transduction pathways downstream of receptor tyrosine kinases
- Insulin and IOGF-1 receptor signaling via the mTOR pathway
- mTOR-S6 kinase feedback loop leading to downregulation of the IRS1 docking protein and insulin resistance
- History of Eph receptor tyrosine kinases and their ephrin ligands
- Bidirectional signaling via Eph-ephrin interactions on neighboring cells
- Simultaneous signaling by EphAs and ephrin As in motor neurons
- Compartmentalized signaling by receptor tyrosine kinases and their ligands through localization to discrete membrane domains
- Protein kinases and human disease
- Human cancer genes and protein kinases
- Protein kinases and phosphatases and cancer
- The long road to Gleevec
Links
Series:
Categories:
Talk Citation
Hunter, T. (2007, October 1). Receptor tyrosine kinases - function, families and evolution [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/MDRF5726.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tony Hunter has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.